Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Jakafi (ruxolitinib)
- nepafenac ophthalmic
Interactions between your drugs
nepafenac ophthalmic ruxolitinib
Applies to: nepafenac ophthalmic, Jakafi (ruxolitinib)
Using nepafenac ophthalmic together with ruxolitinib may increase the risk of bleeding. Nonsteroidal anti-inflammatory drugs including those in topical preparations such as eye drop and analgesic cream/ointment/gel can interfere with clotting and cause bleeding, especially when used regularly or for prolonged periods. You should seek immediate medical attention if you experience any unusual bleeding or bruising, or have other signs and symptoms of bleeding such as dizziness; lightheadedness; red or black, tarry stools; coughing up or vomiting fresh or dried blood that looks like coffee grounds; severe headache; and weakness. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
ruxolitinib food
Applies to: Jakafi (ruxolitinib)
Do not consume grapefruit or grapefruit juice during treatment with ruxolitinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of ruxolitinib. This may increase the risk of side effects that affect your bone marrow function, resulting in low numbers of different types of blood cells. You may be more likely to develop anemia, bleeding problems, or infections. Contact your doctor if you experience potential signs and symptoms of these conditions such as paleness, fatigue, dizziness, fainting, unusual bleeding or bruising, fever, chills, sore throat, body aches, or other flu-like symptoms. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Rayos
Rayos (prednisone, delayed-release) is used to treat rheumatoid arthritis, polymyalgia rheumatica ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Besremi
Besremi (ropeginterferon alfa-2b-njft) is used for the treatment of adults with polycythemia vera ...
Trexall
Trexall is used for acute lymphoblastic leukemia, acute lymphocytic leukemia, breast cancer ...
Rasuvo
Rasuvo is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.